Fundraising Fox
/Companies
Sign in

VerImmune

Bethesda, US · Founded 2019 · Delaware corporation · 12 employees on LinkedIn · 7 known investors

Find your way into VerImmune

Sign up to see every warm intro you have to VerImmune

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the VerImmune team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

VerImmune develops immunotherapy medicines that redirect pre-existing immune memory toward cancer cells to achieve tumor destruction with low toxicity. The company targets cancer patients across a broad range of cancer types.

BiotechHealthtechMedical Devices

Founders & leadership

VerImmune was founded in 2019 by JOSHUA WANG.

JWJOSHUA WANG
JOSHUA WANGFounding CEO & PresidentJoshua Wang has worked in founding and operating early-stage biotech companies with technical expertise in virology, vaccines, and immunology. He has lived and worked across Singapore, the UK, and the USA.
JT
JOHN TROYERNamed on SEC filing

Board

CP
CYNTHIA POHBoard director
KK
KEVIN KOH RONGSHENGBoard director
HSHAOLIN SUNG
HAOLIN SUNGMember Board of Directors
CHCHE HSU
CHE HSUBoard Member
MNMARTA NEW
MARTA NEWBoard director
RPROGER POMERANTZ
ROGER POMERANTZFounding Director, of the Board of Directors

Investors · 7

Mana Ventureslisted by Mana VenturesEstero

How we know: funding news · verimmune.com · Not right? Tell us

Maryland TEDCOlisted by Maryland TEDCOColumbia · $500K – $1.5M
Symbiotic Ventureslisted by Symbiotic VenturesRidgewood
Ulu Ventureslisted by Ulu VenturesPalo Alto · $2M

How we know: Ulu Ventures's portfolio page · funding news · press coverage · Not right? Tell us

NuFund Venture GroupreportedSan Diego · $1M

How we know: press coverage · Not right? Tell us

Also in the syndicate · 1

Proxima VClead

Funding

SEC filings, press & company announcements

$5.9M disclosed across 2 of 3 rounds · 2022–2024

▶$4.5MraisedSep 2024 · 6 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • CYNTHIA POHDirector
  • KEVIN KOH RONGSHENGDirector
  • HAOLIN SUNGDirector
  • CHE HSUDirector
  • MARTA NEWDirector
  • JOSHUA WANGExecutive Officer, Director, Promoter
  • ROGER POMERANTZDirector
Offering amount
$8M
Amount sold
$4.5M
Minimum investment
$22.8K
First sale
Aug 2024
Incorporated
Corporation, Delaware, 2019
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.4MraisedMar 2022 · 9 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • ROGER POMERANTZDirector
  • JOHN TROYERExecutive Officer
  • CYNTHIA POHDirector
  • JOSHUA WEIYUAN WANGExecutive Officer, Director, Promoter
  • KEVIN KOH RONGSHENGDirector
Offering amount
$2.5M
Amount sold
$1.4M
Minimum investment
$25K
Proceeds to insiders
$125K
First sale
Mar 2022
Incorporated
Corporation, Maryland, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 5

EvolveImmune TherapeuticsEvolveImmune develops immunotherapy treatments for cancer patients. The company focuses on discovering and developing novel biotherapeutics in immuno-oncology and related immune-mediated diseases.
InfinimmuneInfinimmune discovers and develops antibody therapeutics using proprietary sequencing technology and AI-powered optimization. The company serves pharmaceutical and biotech partners developing treatments across 350+ disease targets.
InimmuneInimmune is a clinical-stage biotech company developing immunotherapies for allergy, cancer, infectious, and autoimmune diseases. The company combines immunology and vaccine expertise to advance its clinical and pre-clinical pipeline.
ImmuneeringImmuneering develops Deep Cyclic Inhibitors, a class of oncology medicines designed to pulse dosing faster than cancer's adaptive mechanisms to limit resistance and reduce side effects. The company targets more durable tumor control and improved tolerability for cancer patients.
Immunomic TherapeuticsImmunomic Therapeutics develops nucleic acid immunotherapy platforms, particularly self-amplifying RNA and plasmid DNA vaccines, for cancer treatment, allergies, and animal health applications. The company's UNITE® platform leverages lysosomal targeting technology to generate immune responses against CMV, HPV, and other tumor-associated antigens across multiple cancer types and allergic conditions.

Companies working in the same space as VerImmune.

In the news

VerImmune Closes $4.5M First Closing of Pre-Series A Financingfinsmes.com · Sep 2024VerImmune Announces Over $3M Additional Funding — VERIMMUNEverimmune.com · Sep 2023VerImmune Inc Announces Closing of Seed Financing to Further Develop Novel Virus-inspired Particle Immunotherapies — VERIMMUNEverimmune.com · Jul 2022

Frequently asked questions

What does VerImmune do?
VerImmune develops immunotherapy medicines that redirect pre-existing immune memory toward cancer cells to achieve tumor destruction with low toxicity. The company targets cancer patients across a broad range of cancer types.
Who founded VerImmune?
VerImmune was founded by JOSHUA WANG in 2019.
Who are VerImmune's investors?
VerImmune's investors include Gaingels, Mana Ventures, Maryland TEDCO, Symbiotic Ventures, Ulu Ventures, NuFund Venture Group.
How much funding has VerImmune raised?
VerImmune has disclosed $5.9M raised across 2 of its 3 known rounds.
Where is VerImmune headquartered?
VerImmune is headquartered in Bethesda, US.